Single dose of inhaled procaterol has a prolonged effect on exercise performance of patients with COPD

References

• Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW. Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial. European Respiratory Journal 2002; 19: 936–943
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine 2002; 166: 111–117
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine 2003; 167: 211–277
   PubMed Web of Science ®Google Scholar
• Baronti A, Lelli M, Manini G, Verdiani P. Procaterol metered aerosol in patients with chronic obstructive pulmonary disease. International Journal of Clinical Pharmacology Research 1987; 7: 363–368
   PubMedGoogle Scholar
• Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1996; 153: 967–975
   PubMed Web of Science ®Google Scholar
• Berger R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable “fixed” airway obstruction. American Review of Respiratory Disease 1988; 138: 624–629
   PubMedGoogle Scholar
• Borg GA. Psychophysical bases of perceived exertion. Medicine and Science in Sports and Exercise 1982; 14: 377–381
   PubMed Web of Science ®Google Scholar
• Casaburi R, Kukafka D, Cooper CB, Witek TJ, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817
   PubMed Web of Science ®Google Scholar
• Chetta A, Del Donno M, Maiocchi G, Pisi G, Moretti D, Olivieri D. Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. Annals of Allergy 1993; 70: 171–174
   PubMedGoogle Scholar
• Curtis JR. Assessing health-related quality of life in chronic pulmonary disease. Pulmonary Rehabilitation, Lung Biology in Health and Disease, PF Alfred. Marcel Dekker, New York 1996; 329–353
   Google Scholar
• Dyer CA, Singh SJ, Stockley RA, Sinclair AJ, Hill SL. The incremental shuttle walking test in elderly people with chronic airflow limitation. Thorax 2002; 57: 34–38
   PubMed Web of Science ®Google Scholar
• Elpern EH, Stevens D, Kesten S. Variability in performance of timed walk tests in pulmonary rehabilitation programs. Chest 2000; 118: 98–105
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax 1984; 39: 818–822
   PubMed Web of Science ®Google Scholar
• Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PM. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. European Respiratory Journal 1992; 5: 659–664
   PubMed Web of Science ®Google Scholar
• Hoffstein V, Zamel N, McClean P, Chapman KR. Changes in pulmonary function and cross-sectional area of trachea and bronchi in asthmatics following inhalation of procaterol hydrochloride and ipratropium bromide. American Journal of Respiratory and Critical Care Medicine 1994; 149: 81–85
   PubMedGoogle Scholar
• Ikeda A, Nishimura K, Koyama H, Tsukino M, Mishima M, Izumi T. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 48–53
   PubMed Web of Science ®Google Scholar
• Kazuhiro S, Takanobu S, Masahiro S, Hazuki S, Noritaka K, Mayumi D, Chikage K, Tomoko S, Keiyu S, Hitomi T, Hitoshi K, Nobuaki I, Mitunobu H. Effect of β2 receptor agonist in patients with chronic obstructive pulmonary disease: With special reference to the effect on QOL and ADL. Journal of Japan Society for Respiratory Care 2003; 12: 318–325
   Google Scholar
• Kikuchi Y, Yanai M, Taguchi O, Sekizawa K, Hida W, Sasaki H, Takishima T. [New methods for measurement of peripheral airway resistance]. Nihon Kyobu Shikkan Gakkai Zasshi 1989; 27: 1401–1406
   PubMedGoogle Scholar
• Liippo K, Silvasti M, Tukiainen H. Inhaled procaterol versus salbutamol in bronchial asthma. European Journal of Clinical Pharmacology 1991; 40: 417–418
   PubMedGoogle Scholar
• Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000; 161: 1136–1142
   PubMed Web of Science ®Google Scholar
• MacIntyre NR. Chronic obstructive pulmonary disease management: The evidence base. Respiratory Care 2001; 46: 1294–1303
   PubMedGoogle Scholar
• Man WD, Soliman MG, Gearing J, Radford SG, Rafferty GF, Gray BJ, Polkey MI, Moxham J. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2003; 168: 562–567
   PubMed Web of Science ®Google Scholar
• Mazza JA, Tashkin DP, Reed CE. Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. Annals of Allergy 1992; 68: 267–273
   PubMedGoogle Scholar
• Mitsuhashi M, Kimura T, Tateno K, Morikawa A, Kuroume T. Effect of inhaled procaterol hydrochloride in children with bronchial asthma, with particular reference to duration of effect. Journal of Asthma 1985; 22: 203–207
   PubMed Web of Science ®Google Scholar
• Obata T, Matsuda S, Akasawa A, Iikura Y. Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children. Annals of Allergy 1993; 70: 123–126
   PubMedGoogle Scholar
• O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. European Respiratory Journal 2004; 23: 832–840
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. European Respiratory Journal 2001; 18: 914–920
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001; 164: 770–777
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine 2001; 163: 1256–1276
   PubMedGoogle Scholar
• Prefaut CA, Varry A, Vallet G. Pathophysiological basis of exercise training in patients with chronic obstructive lung disease. European Respiratory Review 1995; 5: 27–32
   Google Scholar
• Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62–70
   PubMed Web of Science ®Google Scholar
• Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA. Six-minute walk distance in chronic obstructive pulmonary disease: Reproducibility and effect of walking course layout and length. American Journal of Respiratory and Critical Care Medicine 2003; 167: 1522–1527
   PubMed Web of Science ®Google Scholar
• Shapiro GG, Kemp JP, DeJong R, Chapko M, Bierman CW, Altman LC, Furukawa CT, Meltzer E, Orgel A, Pierson WE. Effects of albuterol and procaterol on exercise-induced asthma. Annals of Allergy 1990; 65: 273–276
   PubMedGoogle Scholar
• Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 1019–1024
   PubMed Web of Science ®Google Scholar
• Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001; 119: 256–270
   PubMed Web of Science ®Google Scholar
• Somand H, Remington TL. Tiotropium: A bronchodilator for chronic obstructive pulmonary disease. Annals of Pharmacotherapy 2005; 39: 1467–1475
   PubMedGoogle Scholar
• Storms WW, Chervinsky P, Bell T, Kemp JP, Brandon ML, Reed CE, Siegel SC, Repsher L. Procaterol metered-dose inhaler: A multiclinic study evaluating the efficacy and safety in patients with asthma. Annals of Allergy 1989; 63: 444–448
   PubMedGoogle Scholar
• van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. European Respiratory Journal 2005; 26: 214–222
   PubMed Web of Science ®Google Scholar
• van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55: 289–294
   PubMed Web of Science ®Google Scholar
• Wadbo M, Löfdahl CG, Larsson K, Skoogh BE, Tornling G, Arweström E, Bengtsson T, Ström K. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. European Respiratory Journal 2002; 20: 1138–1146
   PubMed Web of Science ®Google Scholar
• Yusen R. What outcomes should be measured in patients with COPD?. Chest 2001; 119: 327–328
   PubMed Web of Science ®Google Scholar